**Name of Journal:** *World Journal of Cardiology*

**Manuscript NO:** 47649

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective study***

**One-year outcomes of a NeoHexa sirolimus-eluting coronary stent system with a biodegradable polymer in all-comers coronary artery disease patients: Results from NeoRegistry in India**

Jambunathan R *et al*. NeoHexa stent outcomes in CAD patients

Rajagopal Jambunathan, Dinesh Basavanna, Preeti Vani, Malte Neuss, Prashant Janbandhu

**Rajagopal Jambunathan**, **Dinesh Basavanna**, Cauvery Heart and Multispecialty Hospital, Mysore, Karnataka 570011, India

**Dinesh Basavanna**, Department of Cardiology Mysore Medical College and research institute, Mysore, Karnataka 570001, India

**Preeti Vani**, **Malte Neuss**, **Prashant Janbandhu,** Medical Division, Sahajanand Laser Technology Ltd., Gandhinagar, Gujarat 382027, India

**Malte Neuss**, Manemed Research and Development, Roeckumstr, Bonn 53123, Germany

**ORCID Number:** Rajagopal Jambunathan (0000-0001-7969-3564); Dinesh Basavanna (0000-0003-0361-5441); Preeti Vani (([0000-0001-5665-1062](https://orcid.org/0000-0001-5665-1062)); Malte Neuss ([0000-0003-3046-4140](https://orcid.org/0000-0003-3046-4140));Prashant Janbandhu (0000-0001-5816-4006).

**Author contributions:** Jambunathan R, Basavanna D, Vani P, Neuss M, and Janbandhu P were equally involved in designing the report, collecting and analyzing patient’s clinical data, and preparing the manuscript.

**Supported by** the Sahajanand Laser Technology Ltd., India.

**Institutional review board statement:** This study was approved by the Ethics Committee of Mysore Medical College and Research Institute (EC REG: ECR/134/Inst/KA/2013/RR-16).

**Informed consent statement:** As per IEC, in case of prospective studies, there is a need to obtain informed consent from subjects. However, in our case (a retrospective trial) permission should be taken from the Head of Institution.

**Conflict-of-interest statement:** Mr. Prashant, Dr. Malte, and Ms. Preeti are employees of Sahajanand Laser Technology Ltd., India. All other authors have nothing to disclose.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Prashant Janbandhu, MSc,** Medical Division, Sahajanand Laser Technology Ltd., Gandhinagar, Gujarat 382027, India. [clinical@sltl.com](mailto:clinical@sltl.com)

**Telephone:** +91-72-27039377

**Fax**: +91-79-23287470

**Received:** April 4, 2019

**Peer-review started:** April 4, 2019

**First decision:** June 7, 2019

**Revised:** June 18, 2019

**Accepted:** July 17, 2019

**Article in press:**

**Published online:**

**Abstract**

***BACKGROUND***

Biodegradable polymer drug-eluting stents (BP-DES) have been shown to reduce restenosis rates and have low rates of stent thrombosis. The present postmarketing surveillance assessed the 1-year clinical outcomes of patients who had received NeoHexa DES in real practice.

***AIM***

To investigate the 1-year clinical outcomes of NeoHexa DES in real practice.

***METHODS***

Data obtained from a single-center cohort of patients who had received NeoHexa stents as part of routine treatment for coronary artery disease (CAD) were retrospectively investigated. The primary study endpoint was the rate of major adverse cardiac events (MACEs) defined as the composite of death, myocardial infarction (MI), and target lesion revascularization (TLR) during the follow-up at 1 mo, 6 mo, and 1 year after the index procedure.

***RESULTS***

A total of 129 patients with 172 lesions were enrolled. The most common comorbid conditions were hypertension (49.61%) and diabetes mellitus (39.53%). Procedural success was achieved in all patients, and no in-hospital MACE was reported. The incidence of composite MACE at 30 d, 6 mo, and 1 year was 0.78%, 3.94%, and 4.87%, respectively. The rates of both possible and probable late stent thrombosis were 0.78%. The cumulative incidence of death, MI, and TLR at 1 year was 2.44%, 0.81%, and 1.63%, respectively.

***CONCLUSION***

The relatively low rates of MACE and stent thrombosis in this study support the safety and performance of NeoHexa stents, suggesting that it is an effective alternative to other contemporary stents for the treatment of *de novo* lesions in native coronary arteries.

**Key words:** Sirolimus; Drug-eluting stent; Myocardial infarction; Thrombosis; Coronary artery disease

**© The Author(s) 2019** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Reports have indicated that the use of stents in patients with coronary artery disease has reduced the rates of restenosis. Biodegradable polymer drug eluting stents have been shown to reduce restenosis rates and lower the stent thrombosis rate. Our study assessed the 1-year clinical outcomes of a single-center cohort of patients who had received NeoHexa sirolimus drug-eluting stents in real practice. It showed relatively low rates of major adverse cardiac event and stent thrombosis, which supported the safety and performance of NeoHexa stent as well as its use as an effective alternative to other existing stents.

Jambunathan R, Basavanna D, Vani P, Neuss M, Janbandhu P. One-year outcomes of a NeoHexa sirolimus-eluting coronary stent system with a biodegradable polymer in all-comers coronary artery disease patients: Results from NeoRegistry in India. *World J Cardiol* 2019; In press

**INTRODUCTION**

The prevalence of cardiovascular diseases, particularly coronary artery disease (CAD), is ever-increasing in India and has reached epidemic proportions[1]. Approximately 17% of total deaths were attributed to coronary heart disease in 2001–2003, which increased to 23% in 2010–2013 in India[1,2]. Percutaneous coronary intervention (PCI) is one of the most commonly performed cardiac procedures aimed at improving symptoms and quality of life of patients with CAD[3-5].

The unceasing research over decades in the field of PCI has led to improved devices and treatment strategies. Bare-metal stents (BMS) are able to reduce the rates of restenosis and acute occlusion compared with balloon angioplasty. Subsequently, the advent of drug-eluting stents (DES) has further decreased the rates of restenosis. Of note, first-generation DES were durable polymer DES, and delayed re-endothelialization due to the polymer raised concerns regarding late and very-late stent thrombosis (ST). Despite several efforts to reduce the ST rates of durable polymer DES such as alteration of stent platforms to increase tissue compatibility, modification of the outer layer of the stent surface, and using effective antiproliferative drugs and appropriate polymer carriers, the issue of inflammatory response still persists. Therefore, biodegradable polymer drug-eluting stents (BP-DES) were introduced with anticipation to reduce ST[6-8]. As expected, long-term clinical evidence has demonstrated superiority of BP-DES in reducing very-late ST events compared with durable polymer DES[9-11].

NeoHexa is one of such BP-DES designed with the aim to reduce rates of late ST and was launched in July 2015. The present study investigated the 1-year clinical outcomes of patients who had received this new DES in real clinical practice.

**MATERIALS AND METHODS**

***Study design and patient selection***

Data obtained from a single-center cohort of patients who had received NeoHexa stents as part of routine treatment for CAD between July 2015 and July 2016 at the Cauvery Heart and Multispecialty Hospital, Mysore, were retrospectively investigated in January 2017. The study was conducted in accordance with the Helsinki Declaration and was approved by an independent ethics committee. Verbal informed consent was obtained before collecting data from patients who were contacted to participate in this study. This investigator initiated trial was registered with Clinical Trial Registry of India (CTRI/2018/03/012522)

***Description of device***

NeoHexa is a cobalt-chromium sirolimus-eluting coronary stent system. It is a premounted, balloon expandable DES with a persistent coating of BP carrier, loaded with 1.0 μg/mm2 sirolimus in a slow-release formulation. It is mounted on a rapid exchange percutaneous transluminal coronary angioplasty balloon catheter. It has two radiopaque markers beside the mounted stent for accurate placement. It is available in diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0, and 4.5 mm and in stent lengths of 7, 10, 13, 15, 17, 20, 24, 28, 33, 38, 42, and 45 mm.

***Study procedure and data collection***

This was an all-comer study, and the indications for the angioplasty procedure and technique of stent implantation were as per the discretion of the treating physician. All patients were advised to receive dual antiplatelet therapy with clopidogrel and aspirin. Patients who were not pretreated received a bolus dose of 300-600 mg of clopidogrel or 60 mg of prosugrel and ≥ 100 mg of soluble aspirin just before the procedure.

Data were sourced from clinical notes, including inpatient progress notes and outpatient notes and letters, angiogram reports, and procedural angiographic images. Case report forms were completed for all patients, and data were stored in a secure, off-site database. Follow-up data were collected using either clinical visits or telephonic interactions by using structured questionnaires developed for this study to determine endpoint status at 1 mo, 6 mo, and 1 year after the index procedure. Supporting clinical documents were sought when necessary. Patients with incomplete clinical notes or who were noncontactable *via* telephone were excluded from the analysis.

***Endpoint definitions***

The primary endpoint of the study was the rate of major adverse cardiac events (MACEs) defined as the composite of death, myocardial infarction (MI), and target lesion revascularization (TLR) during the follow-up period after the index procedure. Deaths were categorized as cardiac or noncardiac. Stent thrombosis was evaluated according to the Academic Research Consortium criteria[12]. Procedural success was defined as successful stent placement at the desired position with < 30% residual stenosis.

***Sample size and statistical analysis***

A random sample size of 129 patients was calculated based on the primary endpoint of the study. Categorical data are presented as numbers and percentages. Continuous variables are presented as the mean ± SD. All data were processed using the statistical analysis software SPSS, version 21 or higher (SPSS Inc., Chicago, IL, United States).

**RESULTS**

***Baseline demographic and clinical characteristics***

In total, 129 patients with 172 lesions were enrolled in the study. Baseline demographics and clinical characteristics are summarized in Table 1. Mean age of patients was 56.57 ± 11.73 years, and the majority were men (76.74%). The most common comorbid conditions were hypertension (49.61%), followed by diabetes mellitus (39.53%). Over 70% of patients presented with angina class II and above.

***Lesion and procedural characteristics***

Most lesions were located in the left anterior descending artery (LAD; 42.44%), right coronary artery (RCA; 32.56%), and left circumflex artery (LCx; 21.51%), and the majority of them were positioned proximal (48.26%), mid (31.39%), or distal (12.79%) (Table 2). Approximately 72% of patients had a lesion length ranging 20–40 cm. The average stenosis rate was 88.12%. Bifurcation and thrombotic lesions comprised approximately 11% of all lesions. Approximately 95% of lesions were moderate- to high-risk lesions as per ACC/AHA criteria, and most (96.51%) lesions had a Thrombolysis in Myocardial Infarction (TIMI) flow grade below 3. The average length and diameter of the stents were 27.30 ± 9.20 mm and 2.98 ± 0.69 mm, respectively. The average number of stents per patient was 1.34 ± 0.53, and pre- and post-dilation was performed in 97.67% and 26.16% of patients, respectively. Procedural success was achieved in all patients, and no in-hospital MACE was reported.

***Clinical outcomes during follow-up***

The incidence of composite of MACE at 30 d was 0.78% with one cardiac death. MACE rates during the follow-up duration are depicted in Table 3. In brief, MACEs were reported in six (4.87%) patients at 1 year, consisting of two cardiac deaths, one noncardiac death, one (0.81%) MI event, and two (1.63%) TLR events. Both TLR events were PCI, and the patients recovered after treatment. As shown in Table 4, the cumulative rate of ST was 1.55% (2/129) at 1 year and late ST was ARC-possible ST.

**DISCUSSION**

The present postmarketing surveillance study was conducted to support the safety of NeoHexa stents for treatment of coronary artery lesions in real-world clinical practice. One-year follow-up results demonstrated the favorable safety and performance of the stent with low rates of MACE and ST of 4.87% and 1.55%, respectively.

We evaluated real-world data of NeoHexa in an unselected clinical practice population with diverse clinical profiles, which included diabetes (39.53%), hypertension (49.61%), bifurcation and thrombotic lesions (11.04%), and ACC/AHA type B and C lesions (94.77%). The presentation of patients was similar to that reported in studies of other similar stents[13,14]. The NeoHexa stent is designed to have thin struts (60 μm) on a cobalt-chromium platform with a unique and innovative “s” link and an alternate “C” link, which provides high radial strength and no foreshortening, making it ideal for all lesion locations including ostial lesions.

The first-generation DES were built on bulky stent platforms, making deliverability quite challenging[15]; however, the thin struts and growth of 8% from nominal pressure to rated burst pressure of this new-generation NeoHexa DES offer good deliverability and conformability, thereby allowing complete deployment and good wall apposition. The design leads to a minimal balloon overhang, minimizing the risk of edge dissection/injury, which is a common procedural complication of PCIs. The finding that procedural success was achieved in 100% of patients in this study supports these claims.

Compared with BMS, first-generation DES with a durable polymer have reduced the rate of restenosis but are associated with higher late ST[11]. Delayed endothelial healing secondary to a hypersensitivity reaction to the durable polymer could be responsible for the observed high rate of ST with such DES[16-18]. BP-DES were developed to address this potential limitation of durable polymer DES. The drug encapsulated in polymer is completely released within 3–9 mo, and the polymer also gradually degrades into carbon dioxide and water molecules. Therefore, BP-DES initially provide antiproliferative benefits similar to durable polymer DES and later behave like BMS once drug delivery and polymer biodegradation are complete[19]. Given the importance of ST in evaluating the overall performance of DES, we estimated the ST rate in our study. The rates of both possible and probable late ST was 0.78% in the present study, which are comparable to those of other standard BP-DES such as sirolimus-eluting Orsiro stents (0.4%), biolimus-eluting Nobori stents (1.2%), and Biolimus A9 stents (0.2%) at 1-year follow-up[14,20]. The low rate of ST observed in our study could be attributed to complete wall apposition of the NeoHexa stent and appropriate endothelial healing over the 1-year period.

Although there is no scientific difference between indigenously developed DES *vs* those developed and marketed by global manufacturers, cost effectiveness remains a key factor in the decision-making process for patients and health care providers in India[21]. The most promising results of this retrospective study are 100% procedural success rate and low rates of MACE (4.87%). MACE rates in our study are comparable to previously reported incidence rates for other BP-DES: Endeavor stent (12.9%), NOBORI stent (11%), and Metafor SES (1.6%)[13,22,23]. Moreover, our results are comparable to the rate observed in the SPIRIT II trial (7.2%)[7].

A major limitation of the present study is the observational design and retrospective analysis of data. However, observational data allow true representation of all-comer population unlike randomized trials with restricted enrollment criteria. In addition, a 1-year follow-up period might not be adequate to evaluate the safety and performance of NeoHexa DES. Therefore, our results must be further substantiated in well-designed studies with longer follow-up duration.

In conclusion, the relatively low rates of MACE and ST in this cohort of patients after 1 year of follow-up support the favorable safety and performance of NeoHexa stents. Product characteristics such as advanced sent design with the use of biodegradable polymer that provides high radial strength, minimal balloon overhang, low recoil, and uniform scaffolding could be responsible for these results. NeoHexa could be suggested as an effective alternative to other contemporary stents available in the market for the treatment of *de novo* lesions in native coronary arteries.

**Acknowledgements**

Authors would like to thank CBCC Global Research for providing medical writing assistance in the preparation of this manuscript which was funded by Sahajanand Laser Technology Ltd., India.

**ARTICLE HIGHLIGHTS**

***Research background***

Biodegradable polymer drug-eluting stents have been shown to reduce restenosis rates and have low rates of stent thrombosis. Thus, this post-marketing surveillance assessing outcomes after 1 year of treatment shows the real implications of biodegradable drug eluting stents.

***Research motivation***

Proving the real-life reduced restenosis rates of biodegradable stents was the motivation behind this study. Key problems were the rates of major adverse cardiac events (MACEs) myocardial infarction, and target lesion revascularization. Solving this would increase patient survival rate.

***Research objectives***

The main objective was to identify the rate of MACE during the follow-up period at 1 mo, 6 mo, and 1 year after the procedure completion.

***Research methods***

This was a retrospective analysis of a single-centre cohort of patients who had received NeoHexa stents as part of routine treatment for CAD.

***Research results***

Procedural success was achieved in all patients, and no in-hospital MACE was reported. The incidence of composite MACE at 30 d, 6 mo, and 1 year was 0.78%, 3.94%, and 4.87%, respectively.

***Research conclusions***

Relatively low rates of MACE and stent thrombosis in this study support the safety and performance of NeoHexa stents, suggesting that it is an effective alternative for treatment of *de novo* lesions.

***Research perspectives***

Our results must be further substantiated in well-designed studies with longer follow-up duration.

**REFERENCES**

1 **Gupta R**, Mohan I, Narula J. Trends in Coronary Heart Disease Epidemiology in India. *Ann Glob Health* 2016; **82**: 307-315 [PMID: 27372534 DOI: 10.1016/j.aogh.2016.04.002]

2 **Registrar General of India.** Sample Registration System Report Office of the Registrar General, New Delhi, India, 2011. Available from URL: http://www.censusindia.gov.in/vital\_statistics/causesofdeath.html

3 **Boden WE**, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med* 2007; **356**: 1503-1516 [PMID: 17387127 DOI: 10.1056/NEJMoa070829]

4 **Sedlis SP**, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB, Kostuk W, Chaitman BR, Berman D, Lorin JD, Dada M, Weintraub WS, Boden WE; COURAGE Trial Investigators. Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. *N Engl J Med* 2015; **373**: 1937-1946 [PMID: 26559572 DOI: 10.1056/NEJMoa1505532]

5 **Fihn SD**, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB 3rd, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV; American College of Cardiology Foundation. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation* 2012; **126**: 3097-3137 [PMID: 23166210 DOI: 10.1016/j.jacc.2012.07.013]

6 **Hamon M**, Niculescu R, Deleanu D, Dorobantu M, Weissman NJ, Waksman R. Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions (BIOFLOW-I): a prospective, first-in-man study. *EuroIntervention* 2013; **8**: 1006-1011 [PMID: 23339805 DOI: 10.4244/EIJV8I9A155]

7 **Garg S**, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hébert K, Sudhir K, Boland J, Huber K, Garcia E, te Riele JA; SPIRIT II Investigators. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). *JACC Cardiovasc Interv* 2009; **2**: 1190-1198 [PMID: 20129545 DOI: 10.1016/j.jcin.2009.10.002]

8 **Finn AV**, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. *Arterioscler Thromb Vasc Biol* 2007; **27**: 1500-1510 [PMID: 17510464 DOI: 10.1161/ATVBAHA.107.144220]

9 **Parsa E**, Saroukhani S, Majlessi F, Poorhosseini H, Lofti-Tokaldany M, Jalali A, Salarifar M, Nematipour E, Alidoosti M, Aghajani H, Amirzadegan A, Kassaian SE. Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study. *Tex Heart Inst J* 2016; **43**: 126-130 [PMID: 27127426 DOI: 10.14503/THIJ-14-4997]

10 **Goyal BK**, Kalmath BC, Kawar R, Sharma A, Khemnar B, Rangnekar H. Experience with BioMatrix BES and other DES in all-comers setting: a retrospective overview. *Indian Heart J* 2013; **65**: 678-682 [PMID: 24407537 DOI: 10.1016/j.ihj.2013.10.014]

11 **Stefanini GG**, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Jüni P, Schömig A, Windecker S, Kastrati A. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. *Eur Heart J* 2012; **33**: 1214-1222 [PMID: 22447805 DOI: 10.1093/eurheartj/ehs086]

12 **Cutlip DE**, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation* 2007; **115**: 2344-2351 [PMID: 17470709 DOI: 10.1161/CIRCULATIONAHA.106.685313]

13 **Prakasa Rao VS,** Narayana Rao ASV, Kapardhi PLN, Shah PK, Viswanath R, Mehetre SG, Srivastava AK. Safety and Performance of Sirolimus-Eluting Coronary Stent System with Biodegradable Polymer: A Retrospective Analysis in Real-World Patient Population. *World J Cardiovasc Dis* 2017; **7**: 163 [DOI: 10.4236/wjcd.2017.75015]

14 **Mehta AB**, Chandra P, Dalal J, Shetty P, Desai D, Chocklingam K, Prajapati J, Kumar P, Magarkar V, Vasawada A, Goyal BK, Kumar V, Rao VS, Babu R, Parikh P, Kaul U, Patil A, Mhetre T, Rangnekar H. One-year clinical outcomes of BioMatrix™-Biolimus A9™ eluting stent: the e-BioMatrix multicenter post marketing surveillance registry in India. *Indian Heart J* 2013; **65**: 593-599 [PMID: 24206883 DOI: 10.1016/j.ihj.2013.08.031]

15 **Navarese EP**, Kowalewski M, Kandzari D, Lansky A, Górny B, Kołtowski L, Waksman R, Berti S, Musumeci G, Limbruno U, van der Schaaf RJ, Kelm M, Kubica J, Suryapranata H. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. *Open Heart* 2014; **1**: e000064 [PMID: 25332803 DOI: 10.1136/openhrt-2014-000064]

16 **Finn AV**, Nakazawa G, Kolodgie FD, Virmani R. Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing? *JACC Cardiovasc Interv* 2009; **2**: 300-302 [PMID: 19463440 DOI: 10.1016/j.jcin.2009.01.004]

17 **Nebeker JR**, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. *J Am Coll Cardiol* 2006; **47**: 175-181 [PMID: 16386683 DOI: 10.1016/j.jacc.2005.07.071]

18 **Joner M**, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. *J Am Coll Cardiol* 2006; **48**: 193-202 [PMID: 16814667 DOI: 10.1016/j.jacc.2006.03.042]

19 **Vorpahl M**, Finn AV, Nakano M, Virmani R. The bioabsorption process: tissue and cellular mechanisms and outcomes. *EuroIntervention* 2009; **5** Suppl F: F28-F35 [PMID: 22100673 DOI: 10.4244/EIJV5IFA5]

20 **Jensen LO**, Thayssen P, Maeng M, Ravkilde J, Krusell LR, Raungaard B, Junker A, Terkelsen CJ, Veien KT, Villadsen AB, Kaltoft A, Tilsted HH, Hansen KN, Aaroe J, Kristensen SD, Hansen HS, Jensen SE, Madsen M, Bøtker HE, Berencsi K, Lassen JF, Christiansen EH. Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial. *Circ Cardiovasc Interv* 2016; **9**: e003610 [PMID: 27412869 DOI: 10.1161/CIRCINTERVENTIONS.115.003610.]

21 **Sastry BKS**, Nallamalla KR, Kumar N, Kodati D, Menon R. One-year clinical outcomes of different coronary drug eluting stents-Data from a prospective registry. *Indian Heart J* 2018; **70**: 580-583 [PMID: 30170658 DOI: 10.1016/j.ihj.2018.05.012]

22 **Maeng M**, Tilsted HH, Jensen LO, Kaltoft A, Kelbæk H, Abildgaard U, Villadsen AB, Krusell LR, Ravkilde J, Hansen KN, Christiansen EH, Aarøe J, Jensen JS, Kristensen SD, Bøtker HE, Madsen M, Thayssen P, Sørensen HT, Thuesen L, Lassen JF. 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents. *JACC Cardiovasc Interv* 2012; **5**: 812-818 [PMID: 22917452 DOI: 10.1016/j.jcin.2012.04.008]

23 **Natsuaki M**, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T. Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial. *Circ Cardiovasc Interv* 2015; **8**: e002817 [PMID: 26446596 DOI: 10.1161/CIRCINTERVENTIONS.115.002817]

**P-Reviewer:** Exbrayat JM **S-Editor:** Ma YJ **L-Editor:** Wang TQ **E-Editor:**

**Specialty type:** Cardiac and cardiovascular systems

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Demographic and baseline clinical characteristics**

|  |  |
| --- | --- |
| Characteristic | *n* = 129 patients |
| Patient demographics |  |
| Age, yr | 56.57 ± 11.73 |
| Male | 99 (76.74) |
| Baseline medical history |  |
| Diabetes mellitus | 51 (39.53) |
| Hypertension | 64 (49.61) |
| Smoking | 11 (8.53) |
| Family history of coronary artery disease | 04 (3.10) |
| History of alcohol consumption | 05 (3.88) |
| Renal disease | 01 (0.77) |
| Atrial fibrillation | 01 (0.77) |
| Cardiac status - Angina class |  |
| I | 08 (6.20) |
| II | 26 (20.15) |
| III | 71 (55.04) |
| IV | 23 (17.83) |
| Unknown | 01 (0.77) |

Data are presented as the mean ± SD or *n* (%).

**Table 2 Lesion and procedural characteristics (*n* = 129 patients and 172 lesions)**

|  |  |
| --- | --- |
| Characteristic | *n* = 172 lesions |
| Target vessel location |  |
| LAD | 73 (42.44) |
| LCx | 37 (21.51) |
| RCA | 56 (32.56) |
| Ramus | 03 (1.74) |
| Other | 03 (1.74) |
| Target lesion location |  |
| Ostial | 05 (2.91) |
| Proximal | 83 (48.26) |
| Mid | 54 (31.39) |
| Distal | 22 (12.79) |
| Unknown | 08 (4.65%) |
| Lesion length |  |
| <20 mm | 39 (22.67) |
| 20–40 mm | 124 (72.09) |
| >40 mm | 08 (4.65) |
| Stenosis | 88.12 |
| Bifurcation | 3 (1.74) |
| Thrombotic lesions | 16 (9.30) |
| ACC/AHA lesion type |  |
| A | 09 (5.23) |
| B | 92 (53.49) |
| C | 71 (41.28) |
| TIMI flow grade at baseline |  |
| 0 | 45 (26.16) |
| 1 | 49 (28.49) |
| 2 | 72 (41.86) |
| 3 | 05 (2.91) |
| Unknown | 01 (0.58) |
| Average stent length, mm | 27.30 ± 9.20 |
| Average stent diameter, mm | 2.98 ± 0.69 |
| Average stent per patient | 1.34 ± 0.53 |
| Predilation | 168 (97.67) |
| Postdilation | 45 (26.16) |

|  |
| --- |
| Data are presented as the mean ± SD or *n* (%). ACC: American College of Cardiology; AHA: American Heart Association; LAD: Left anterior descending; LCx: Left circumflex; RCA: Right coronary artery; TIMI: Thrombolysis in Myocardial Infarction. |

**Table 3 Mortality, morbidity, and major adverse cardiac events, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Event | In-hospital | 1 mo | 6 mo | 1 yr |
| MACE | 0 | 01 (0.78) | 05 (3.94) | 06 (4.87) |
| Death | 0 | 01 (0.78) | 03 (2.36) | 03 (2.44) |
| Myocardial infarction | 0 | 0 | 01 (0.79) | 01 (0.81) |
| Clinically driven TLR | 0 | 0 | 01 (0.79) | 02 (1.63) |

MACE: Major adverse cardiac event; TLR: Target lesion revascularization.

**Table 4 Stent thrombosis, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| Timing of stent thrombosis | Incidence | Type of stent thrombosis | Incidence |
| Early | 0 | Definite | 0 |
| Late | 01 (0.78) | Probable | 02 (1.55) |
| 01 (0.78) | Possible |